Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
A judge has expressed frustration at the slow pace of the Sydney light rail class action, forcing both parties to commit to a timetable that will push the proceeding more rapidly towards a final hearing.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
Two GPS tracking patents at the heart of a David vs. Goliath battle between Domino’s and a Sydney-based startup were foreshadowed by a patent owned by Uber, the pizza chain giant told a court Friday.